{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:40:59Z","timestamp":1792784459206,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY13574"],"award-info":[{"award-number":["EY13574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK35124"],"award-info":[{"award-number":["DK35124"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EB00415"],"award-info":[{"award-number":["EB00415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK72517"],"award-info":[{"award-number":["DK72517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSL Ltd (Victoria, Australia)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T15:26:21Z","timestamp":1518103581000},"page":"345-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in\u00a0vitro and rat models of neuromyelitis optica"],"prefix":"10.1016","volume":"133","author":[{"given":"Lukmanee","family":"Tradtrantip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Spirig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Baz","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.02.002_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21310","article-title":"A\u00a0multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)","volume":"21","author":"Absoud","year":"2017","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jns.12218","article-title":"Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series","volume":"22","author":"Adrichem","year":"2017","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","article-title":"Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG","volume":"127","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","article-title":"Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid","volume":"254","author":"Asgari","year":"2013","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker","year":"2004","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/jns5.12048","article-title":"Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies","volume":"18","author":"Berger","year":"2013","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000019076","article-title":"c1q knock-out mice for the study of complement deficiency in autoimmune disease","volume":"15","author":"Botto","year":"1998","journal-title":"Exp. Clin. Immunogent"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib12","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib14","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1038\/srep09526","article-title":"Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications","volume":"5","author":"Czajkowsky","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/CCM.0b013e31823779ca","article-title":"Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis","volume":"40","author":"Esen","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2009.12.004","article-title":"Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin","volume":"9","author":"Galeotti","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J.\u00a0Neuroinflam"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091407","article-title":"Efficacy of polyvalent Human immunoglobulins in an animal model of neuromyelitis optica evoked by intrathecal anti-aquaporin 4 antibodies","author":"Gr\u00fcnewald","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458506070145","article-title":"Neuromyelitis optica with clinical and histopathological involvement of the brain","volume":"13","author":"Hengstman","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib27","article-title":"Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice","volume":"14","author":"Jain","year":"2012","journal-title":"Arthritis Res."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib30","first-page":"627","article-title":"Combination of cyclosporin A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.autrev.2015.04.003","article-title":"The role of intravenous immunoglobulin in the treatment of rheumatoid arthritis","volume":"14","author":"Katz-Agranov","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib33","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2007.03.016","article-title":"Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin","volume":"186","author":"Lin","year":"2007","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib35","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A\u00a0role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology-mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1742-2094-9-224","article-title":"Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury","volume":"9","author":"Nguyen","year":"2012","journal-title":"J.\u00a0Neuroinflam"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jns5.12022","article-title":"Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)","volume":"18","author":"Niknami","year":"2013","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib41","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","article-title":"Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica","volume":"46","author":"Okada","year":"2007","journal-title":"Intern. Med"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between IgG-Fc valency and Fc\u03b3R activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib45","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/1352458510382324","article-title":"Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of a perivascular astrocytes","volume":"16","author":"Parratt","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","article-title":"C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in\u00a0vitro and mouse models of neuromyelitis optica","volume":"125","author":"Phuan","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","volume":"229","author":"Piepers","year":"2010","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","article-title":"Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica","volume":"225","author":"Ratelade","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.molimm.2014.06.003","article-title":"Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica","volume":"62","author":"Ratelade","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib52","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.4049\/jimmunol.162.6.3448","article-title":"Polymerization of IgA and IgM: role of Cys309\/Cys414 and the secretory tailpiece","volume":"162","author":"Sorensen","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib53","unstructured":"Spirig, R., Campbell, I.K., Koernig, S., Chen, C.G., Lewis, B.J.B., Butcher, R., Muir, I., Taylor, S., Chia, J., Leong, D., Simmonds, J., Scotney, P., Schmidt, P., Fabri, L., Hofmann, A., Jordi, M., Spycher, M.O., Cattepoel, S., Brasseit, J., Panousis, C., Rowe, T., Branch, D.R., Morelli, A.B., K\u00e4sermann, F., Zuercher, A.W., Unique rIgG1 Fc hexamers inhibit antibody-mediated disease via complement and FcgRs. [Submitted]."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib55","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bpa.12085","article-title":"Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO","volume":"23","author":"Verkman","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","article-title":"Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00401-002-0568-y","article-title":"Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis","volume":"104","author":"Weishaupt","year":"2002","journal-title":"Acta Neuropathol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2018.02.002_bib59","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk","year":"2013","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib60","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.2174\/138161212802502314","article-title":"Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system","volume":"18","author":"Winkelmann","year":"2012","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40478-017-0417-9","article-title":"Marked central nervous system pathology in CD59 knockout rats following passive transfer of neuromyelitis optica immunoglobulin G","volume":"5","author":"Yao","year":"2017","journal-title":"Acta Neurolpathol. Commun"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","article-title":"IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy","volume":"82","author":"Yuki","year":"2011","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.02.002_bib63","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.4049\/jimmunol.168.10.5047","article-title":"SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells","volume":"168","author":"Yusa","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2018.02.002_bib64","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex\u00a0vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann. Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:33:45Z","timestamp":1693506825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":64,"alternative-id":["S0028390818300595"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.002","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in\u00a0vitro and rat models of neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}